Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project LaCasce, A., Vandergrift, J. L., Rodriguez, M. A., Crosby, A. L., Lepisto, E. M., Czuczman, M. S., Nademanee, A. P., Blayney, D. W., Gordon, L. I., Millenson, M., Vanderplas, A., Abel, G. A., Zelenetz, A. D., Friedberg, J. W. AMER SOC HEMATOLOGY. 2009: 167-168
View details for Web of Science ID 000272725800404